If you need more lookups,
subscriptions start at $34 USD/month.
Tanja Obradovic Location
Dresher, PA, US
Tanja Obradovic Work
Vice President, Medical and Scientific Strategy, Oncology @ (February 2026 - Present)
Chief Medical Strategy Officer @ (November 2025 - Present)
Consultant, Oncology Drug Development @ (October 2025 - February 2026)
Oncology Medical Strategy Advisor @ (January 2025 - January 2026)
Vice President, Oncology Drug Development Solutions, Scientific and Medical Affairs @ (January 2022 - November 2024)
Senior Scientific Director, Cell Therapy and Redirected Immunity, Oncology Clinical Science @ (August 2020 - January 2022)
Director, Medical Affairs Strategy Lead, US Oncology Health Systems @ Merck (September 2018 - July 2020)
Associate Director, Oncology Global Regulatory Affairs @ Merck (April 2017 - September 2018)
Associate Director and Principal Clinical Research Scientist Oncology @ Merck (October 2007 - March 2017)
Director of Research @ (May 2003 - September 2007)
Research Assistant Professor @ (February 2001 - May 2003)
NIH Postdoctoral Research Fellow @ Cancer Research Center, Washington State University (January 1999 - June 2000)
Tanja Obradovic Education
Washington State University
Doctor of Philosophy - PhD (Pharmacology and Toxicology)
University of Belgrade
Bachelor of Science - BS (Molecular Biology and Physiology)
Tanja Obradovic Skills
Academic Research
Artificial Intelligence (AI)
Biomarkers
Biopharmaceuticals
Biostatistics
Biotechnology Industry
Business Development
Business Strategy
CRO Management
Cancer Genomics
Cancer Immunotherapy
Cancer Therapeutics
Cell Biology
Cell Therapy
Clinical Development
Clinical Research
Clinical Trials
Collaborative development
Cross-functional Team Leadership
Customer Value Creation
Data Strategies
Development Strategy
Drug Development
Early Development
Executive Leadership
External Relationships
Genetics
Genomics
Global Drug Development
HEOR
Immunology
Immunooncology
In Vitro Diagnostics (IVD)
Investigational New Drug Application (IND)
KOL
KOL Development
Late stage development
Lead Generation
Leadership
Management
Market Access
Market access and strategy
Medical Affairs
Molecular & Cellular Biology
Molecular Biology
Molecular Diagnostics
New Drug Application (NDA)
New Program Development
Oncology
Oncology Clinical Research
Oncology Global and US regulatory, reimbursement and policy landscape
Oncology Medical Affairs strategy and communication
Oncology regulatory submissions
People Management
Pharmaceutical Industry
Pharmaceutical Research
Pharmacoeconomics
Portfolio Management
Program Development
Project Management
Quality Patient Care
Real World Evidence (RWE)
Regulatory Affairs
Regulatory Strategy
Strategic Consulting
Strategy
Target Identification
Targeted Therapies
Thought Leadership
Translational Medicine
Translational Science
U.S. Food and Drug Administration (FDA)
Tanja Obradovic Summary
Tanja Obradovic, based in Dresher, PA, US, is currently a Vice President, Medical and Scientific Strategy, Oncology at Novotech. Tanja Obradovic brings experience from previous roles at HopeAI, Arc Nouvel Clinical Development Consulting LLC, Mercurial AI and ICON plc. Tanja Obradovic holds a Doctor of Philosophy - PhD in Pharmacology and Toxicology @ Washington State University. With a robust skill set that includes Academic Research, Artificial Intelligence (AI), Biomarkers, Biopharmaceuticals, Biostatistics and more. Tanja Obradovic has 3 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Tanja Obradovic?
Find contact details for 700 million professionals.